Pharmaceutical Technology

MAY 1, 2023

CTH-004 is developed by genetically altering patient T cells for inserting a chimeric antigen receptor (CAR) to target a marker (TAG-72) on ovarian cancer cells and delete genes which are involved in T cell function suppression. Shunxi will also hold an option to negotiate rights to other CAR-T products, which include the licenced IP.

Gene Therapy 130

Gene Therapy Gene Development Clinical Trials 130

Rethinking Clinical Trials

AUGUST 3, 2023

As researchers, we are producers and consumers of the medical literature. Publishers will need to rethink how to identify who is saying things and what are their credentials to make sure the ideas in the scientific literature are coming from humans who are trustworthy. Learn more Read Misinformation in and about science.

Medicine 130

Medicine Research Vaccination Vaccine 130

Pharmaceutical Technology

APRIL 13, 2023

Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

Gene Therapy 147

Gene Therapy Gene FDA Approval Licensing 147

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

Gene Therapy 147

Gene Therapy Gene Engineer Production 147

Intouch Solutions

APRIL 11, 2024

but others must be external such as: electronic health records, prescription data, medical literature, social media, and more. This process is relatively straightforward when high-value medical-scientific content is readily available. Some of them could be internal (CRM data and physicians profiling, etc.)

Compliance 52

Compliance Marketing Drugs Pharma Companies 52

Pharmaceutical Technology

JUNE 21, 2023

The high price tag may be hard to defend , but with lifetime treatment costs for haemophilia B reaching as high as $23m for some, the single-dose treatment could prove far more cost-effective. Despite the limited market, the price tags of haemophilia make it potentially lucrative. Haemophilia B is a rare condition.

Gene Therapy 246

Gene Therapy Gene Protein Sales 246